

## Introducing a One-Page Adult Preventive Health Care Schedule: USPSTF Recommendations at a Glance

PAUL F. SWENSON, MD, *El Rio Community Health Center, Tucson, Arizona*

MARK H. EBELL, MD, MS, *University of Georgia College of Public Health, Athens, Georgia*

The U.S. Preventive Services Task Force (USPSTF) is an independent voluntary panel of experts in primary care, prevention, and evidence-based practice. As of April 2016, the USPSTF has recommendation statements for more than 80 active topics, most of which are endorsed by the American Academy of Family Physicians.<sup>1</sup> Its process has been recognized by the Institute of Medicine as a model for development of evidence-based practice guidelines.<sup>2</sup>

However, numerous barriers exist to implementing these guidelines, including knowledge, time, insurance, and social barriers.<sup>3</sup> For example, knowledge of USPSTF colorectal cancer screening components ranged from 22% to 53% in first- through third-year medical residents.<sup>4</sup> One recent survey from the Centers for Disease Control and Prevention (CDC) found significant gaps in physicians' knowledge regarding the value of screening tests for ovarian and colorectal cancer.<sup>5</sup> Another survey found significant levels of nonadherence to USPSTF recommendations, including beginning cervical cancer screening too early, continuing it too long, and performing it annually rather than every three years as recommended.<sup>6</sup>

In addition, recommendations for behavioral counseling are often not implemented. For example, counseling for tobacco cessation was documented in only 21% of visits in which tobacco use was documented.<sup>7</sup> This gap between guideline recommendations and actual practice has the potential to worsen as recommendations become more complex, vary by age group, and increasingly require risk assessment, as with recommendations for mammography, breast cancer

chemoprevention, screening for the *BRCA* gene mutation, and screening for hepatitis B and C virus infections.

With the passage of the Affordable Care Act in 2010, the USPSTF guidelines have taken on new significance. Specifically, grade A and B recommendations must be covered without cost-sharing requirements for patients in nongrandfathered insurance plans.<sup>8</sup> Currently, several resources are available to help physicians understand and implement recommendations:

- Electronic Preventive Services Selector (<http://www.epss.ahrq.gov/PDA/index.jsp>): an electronic resource allowing physicians to input a patient's characteristics to find applicable USPSTF preventive health care recommendations.

- USPSTF website (<http://www.uspreventiveservicestaskforce.org>): a web-based resource of all active and inactive recommendations, as well as those referring to another organization, such as the CDC.

- Guide to Clinical Preventive Services, 2014<sup>9</sup>: an 85-page document (excluding appendices) providing summaries of USPSTF recommendations.

Although these resources are helpful, there has been no concise visual representation of USPSTF recommendations as there is for immunization recommendations (<http://www.cdc.gov/vaccines/schedules/hcp/adult.html#print>). The goals of such a schedule are the following:

- Simplicity (excludes childhood and pregnancy-related topics)
- Familiarity (such as a visual format similar to the CDC vaccine schedule)
- Concise presentation
- Informative
- Easily disseminated

Shown on page 740, the Adult Preventive Health Care Schedule meets these criteria. Although it is not everything a family physician needs to know about screening and prevention, it provides a practical clinical aid. We hope this helps physicians bridge some of the knowledge gaps of USPSTF

recommendations and apply them to their practice.

**EDITOR'S NOTE:** The authors will periodically update the online version of this table and supporting documents throughout the year to make it as current a resource as possible. We plan to run an updated version of this table once a year, similar to the annual immunization schedules. In the online PDF, note that there are links in the main table's risk factors to mini-tables showing what those risk factors are.

Dr. Ebell is Deputy Editor for Evidence-Based Medicine for *AFP*, and a member of the USPSTF. This editorial and accompanying figure were produced independently of the USPSTF and do not necessarily represent the views and policies of the USPSTF.

Dr. Swenson developed the original version of the preventive schedule with coauthors Coya Lindberg, Cynthia Carillo, MD, and Joshua Clutter, MD, as a resident at the University of Arizona.

*Address correspondence to Paul F. Swenson, MD, at paul.swenson@gmail.com. Reprints are not available from the authors.*

Author disclosure: No relevant financial affiliations.

#### REFERENCES

1. U.S. Preventive Services Task Force. Published recommendations. <http://www.uspreventiveservicestaskforce.org/BrowseRec/Index>. Accessed January 30, 2016.
2. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, eds.; Committee on Standards for Developing Trustworthy Clinical Practice Guidelines; Institute of Medicine. *Clinical Practice Guidelines We Can Trust*. Washington, DC: National Academies Press; 2011.
3. Yarnall KS, Pollak KI, Østbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? *Am J Public Health*. 2003;93(4):635-641.
4. Akerman S, Aronson SL, Cerulli MA, Akerman M, Sultan K. Resident knowledge of colorectal cancer screening assessed by web-based survey. *J Clin Med Res*. 2014;6(2):120-126.
5. Miller et al. Physicians' beliefs about effectiveness of cancer screening tests: a national survey of family physicians, general internists, and obstetrician-gynecologists. *Prev Med*. 2014;69:37-42.
6. Centers for Disease Control and Prevention (CDC). Cancer screening—United States, 2010. *MMWR Morb Mortal Wkly Rep*. 2012;61(3):41-45.
7. Jamal A, Dube SR, Malarcher AM, et al. Tobacco use screening and counseling during physician office visits among adults—National Ambulatory Medical Care Survey and National Health Interview Survey, United States, 2005-2009. *MMWR Morb Mortal Wkly Rep*. 2012;61 suppl:38-45.
8. Centers for Medicare and Medicaid Services. Affordable Care Act implementation FAQs—set 12. [https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca\\_implementation\\_faqs12.html](https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12.html). Accessed June 28, 2015.
9. U.S. Preventive Services Task Force. Information for health professionals. August 2014. <http://www.uspreventiveservicestaskforce.org/Page/Name/tools-and-resources-for-better-preventive-care>. Accessed June 28, 2015. ■

# What ails your practice?

**Keep your practice healthy with *Family Practice Management*.**



**Subscribe today.**  
[aafp.org/fpm/subscribe](http://aafp.org/fpm/subscribe)



AMERICAN ACADEMY OF  
FAMILY PHYSICIANS

Family Practice Management

## Adult Preventive Health Care Schedule: Recommendations from the USPSTF (as of April 5, 2016)

To be used in conjunction with USPSTF recommendation statements for additional details (see accompanying tables and references)

**Only grade A/B recommendations are shown**

Age 18 20 21 24 25 35 40 45 49 50 55 65 70 74 75 79 80

### USPSTF screening recommendations

Alcohol misuse <sup>1</sup>	(B)															
Depression <sup>2</sup>	(B)															
Hypertension <sup>3</sup>	(A)															
Obesity <sup>4</sup>	(B)															
Tobacco use and cessation <sup>5</sup>	(A)															
HIV infection <sup>6</sup>	(A)												(A) if at increased risk			
Hepatitis B virus infection <sup>7</sup>	(B) if at increased risk															
Syphilis <sup>8</sup>	(A) if at increased risk															
BRCA gene screening <sup>9</sup>	(B) if appropriate family history															
Chlamydia and gonorrhea <sup>10</sup>	(B) if sexually active								(B) if at increased risk							
Intimate partner violence <sup>11</sup>	(B) childbearing-aged women															
Cervical cancer <sup>12</sup>	(A) Pap smear every 3 years, or every 5 years with human papillomavirus cotesting starting at age 30															
Lipid disorder <sup>13</sup>	(B) if increased CHD risk				(A)											
	(B) if increased CHD risk								(A) if increased CHD risk							
Abnormal glucose/diabetes <sup>14</sup>	(B) if overweight or obese															
Hepatitis C virus infection <sup>15</sup>	(B) if at high risk												(B) birth years 1945-1965		(B) if at high risk	
Colorectal cancer <sup>16</sup>	(A)															
Breast cancer <sup>17</sup>	(B) biennial screening															
Lung cancer <sup>18</sup>	(B) if 30 pack-years and current or former smoker (quit in past 15 years)															
Osteoporosis <sup>19</sup>	(B) if ≥ 9.3% 10-year fracture risk												(B)			
Abdominal aortic aneurysm <sup>20</sup>	(B) if an "ever smoker"															

### USPSTF preventive medications recommendations

Primary prevention breast cancer <sup>21</sup>	(B) if at increased risk and only after shared decision making															
Folic acid supplementation <sup>22</sup>	(A) if capable of conceiving															
Aspirin for cardiovascular risk <sup>23</sup>	(A) if benefit of aspirin > risk															
	(A) if benefit of aspirin > risk															
Fall prevention (vitamin D) <sup>24</sup>	(B) if community dwelling and increased fall risk															

### USPSTF counseling recommendations

Sexually transmitted infection prevention <sup>25</sup>	(B) if at increased risk															
Diet/activity for CVD prevention <sup>26</sup>	(B) if overweight or obese and with additional CVD risk															
Skin cancer prevention <sup>27</sup>	(B) if fair skinned															

Legend	Normal risk	With specific risk factor	Recommendation grades
Recommendation for men and women			A Recommended (likely significant benefit)
Recommendation for men only			B Recommended (likely moderate benefit)
Recommendation for women only			C Do not use routinely (benefit is likely small)
			D Recommended against (likely harm or no benefit)
			I Insufficient evidence to recommend for or against

CHD = coronary heart disease; CVD = cardiovascular disease; HIV = human immunodeficiency virus; USPSTF = U.S. Preventive Services Task Force.

Visual adaptation from recommendation statements by Swenson PF, Lindberg C, Carrilo C, and Clutter J.

**HIV RISK FACTORS**

- IV drug use
- Men who have sex with men
- Other STI
- Requesting STI testing
- Sex exchanged for drugs or money
- Sex with individuals who are IV drug users, bisexual, or HIV positive
- Unprotected sex, including anal intercourse

*HIV = human immunodeficiency virus; IV = intravenous; STI = sexually transmitted infection.*

**CHLAMYDIA AND GONORRHEA RISK FACTORS**

- New or multiple sex partners
- Other STI, including history of STI
- Partner with STI
- Partners who have multiple sex partners
- Sex exchanged for drugs or money
- Sexually active adolescents
- Unprotected sex or inconsistent condom use

*STI = sexually transmitted infection.*

**HEPATITIS B INFECTION RISK FACTORS**

- Human immunodeficiency virus infection
- Infected sex partner
- Intravenous drug use
- Living with an infected individual
- Men who have sex with men
- Origin from regions\* with prevalence  $\geq 2\%$
- U.S.-born children of immigrants from regions\* with prevalence  $\geq 8\%$ , if unvaccinated

*\*—Risk of regions can be found at <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm>.*

**HEPATITIS C INFECTION RISK FACTORS**

- Blood transfusion before 1992
- Chronic hemodialysis
- High-risk sexual behaviors
- Incarceration
- Intravenous or intranasal drug use
- Maternal infection (concern for vertical transmission)
- Unregulated tattoo

**BREAST CANCER RISK FACTORS**

Consider use of a risk-assessment model for patients with a history of biopsy or positive family history

**SYPHILIS RISK FACTORS**

- High-risk sexual behaviors
- Incarceration
- Local prevalence
- Men who have sex with men
- Sex exchanged for money for drugs

**SEXUALLY TRANSMITTED INFECTION RISK FACTORS**

Similar to those risk factors listed previously for sexually transmitted infections; consider local and population-based prevalence in individual risk assessment

**BRCA MUTATION RISK FACTORS**

- Family history of breast cancer:
  - Bilateral
  - Diagnosed before 50 years of age
  - Diagnosed in multiple family members
  - In one or more male family members
  - With a family history of ovarian cancer
- Family member with two BRCA-related cancers

*NOTE: Consider use of validated risk assessment tools to identify patients with pertinent family history.*

**CARDIOVASCULAR DISEASE RISK FACTORS**

- Diabetes mellitus
- Dyslipidemia
- Family history
- Hypertension
- Metabolic syndrome
- Obesity
- Tobacco use

**Adult Preventive Health Care Schedule: Recommendations from the USPSTF**

**Grade A/B Recommendations (with Associated Grade C/D/I Recommendations):**

**Alcohol misuse screening<sup>1</sup>**

(B) Screen adults and provide brief behavioral interventions for risky alcohol use

**Depression screening<sup>2</sup>**

(B) Screen adults with systems for evaluation and management

**Hypertension screening<sup>3</sup>**

(A) Screen adults; exclude white coat hypertension before starting therapy

**Obesity screening<sup>4</sup>**

(B) Screen adults and offer or refer patients with body mass index  $\geq 30$  kg per m<sup>2</sup> to intensive behavioral interventions

**Tobacco use screening<sup>5</sup>**

(A) Screen adults and provide behavioral and U.S. Food and Drug Administration–approved intervention therapy for cessation

(I) IETRFOA electronic nicotine delivery systems for tobacco cessation

**Human immunodeficiency virus screening<sup>6</sup>**

(A) Screen individuals 15 to 65 years of age

(A) Screen older and younger persons who are at increased risk

**Hepatitis B virus infection screening<sup>7</sup>**

(B) Screen adolescents and adults at high risk

**Syphilis screening<sup>8</sup> (UIP)**

(A) Screen individuals at increased risk

(D) Recommend against routine screening if normal risk

**BRCA screening<sup>9</sup>**

(B) Screen women with appropriate family history

(D) Recommend against screening patients without appropriate family history

**Chlamydia and gonorrhea screening<sup>10</sup>**

(B) Screen sexually active women 24 years and younger, and women at increased risk who are 25 years and older

(I) IETRFOA screening sexually active males

**Intimate partner violence screening<sup>11</sup>**

(B) Screen women of childbearing age and refer to appropriate services

(I) IETRFOA screening all vulnerable and elderly patients for abuse or neglect

**Cervical cancer screening<sup>12</sup> (UIP)**

(A) Screen women 21 to 65 years of age

- Papanicolaou smear every three years
- Women 30 to 65 years of age may increase screening interval to five years with cytology and human papillomavirus cotesting

(D) Recommend against screening in women

- Age 20 years and younger

- Older than 65 years if adequately screened previously and no increased risk of cervical cancer

- With hysterectomy (including cervix) without history of cervical intraepithelial neoplasia grade 2 or 3 or cervical cancer

- Younger than 30 years with human papillomavirus testing alone or in combination with cytology

**Lipid disorder screening<sup>13</sup> (UIP)**

(A) Screen men 35 years and older

(A) Screen women 45 years and older at increased risk of CHD

(B) Screen men 20 to 35 years of age and women 20 to 45 years of age at increased CHD risk

(C) No recommendations for or against screening men 20 to 35 years of age and women 20 to 45 years of age without increased CHD risk

**Abnormal glucose and diabetes mellitus type 2 screening<sup>14</sup>**

(B) Screen overweight or obese adults 40 to 70 years of age and refer patients with abnormal glucose levels for intensive counseling for healthy diet and exercise

**Hepatitis C virus infection screening<sup>15</sup>**

(B) Offer one-time screening of patients born between 1945 and 1965

(B) Screen high-risk patients

**Colorectal cancer screening<sup>16</sup> (UIP)**

(A) Screen patients 50 to 75 years of age with fecal occult blood testing, sigmoidoscopy, or colonoscopy

(C) Recommend against routine screening of patients 76 to 85 years of age

(D) Recommend against screening patients 86 years and older

(I) IETRFOA for screening with computed tomography colonography or fecal DNA

**Breast cancer screening<sup>17</sup>**

(B) Biennial screening mammography in women 50 to 74 years of age

(C) Screening is an individualized decision for women 40 to 49 years of age

(I) IETRFOA

- Mammography after 75 years of age

- Screening with digital breast tomosynthesis

- Adjunctive screening in women with dense breast tissue and negative screening mammogram

**Lung cancer screening<sup>18</sup>**

(B) Screen annually with low-dose computed tomography for individuals 55 to 80 years of age with a 30 pack-year history who currently smoke or quit within the past 15 years; consider overall health in decision to screen

**Osteoporosis screening<sup>19</sup> (UIP)**

(B) Screen women 65 years and older

(B) Screen women if fracture risk equal to that of a 65-year-old white woman without other risk factors (9.3% in 10 years by U.S. FRAX [Fracture Risk Assessment] tool)

(I) IETRFOA screening men

*continues*

CHD = coronary heart disease; CVD = cardiovascular disease; IETRFOA = insufficient evidence to recommend for or against; UIP = update in progress; USPSTF = U.S. Preventive Services Task Force.

**Adult Preventive Health Care Schedule: Recommendations from the USPSTF** (continued)**Grade A/B Recommendations (with Associated Grade C/D/I Recommendations):** (continued)**Abdominal aortic aneurysm screening<sup>20</sup>**

- (B) Screen men 65 to 75 years of age who ever smoked (100 or greater lifetime cigarettes) with one-time abdominal aortic aneurysm ultrasonography
- (C) Recommend selective screening of never-smoking men 65 to 75 years of age
- (I) IETFOA women 65 to 75 years of age who ever smoked
- (D) Recommend against routine screening in never-smoking women 65 to 75 years of age

**Primary prevention of breast cancer<sup>21</sup>**

- (B) Recommend shared decision making for medications (such as tamoxifen and raloxifene) that reduce risk of breast cancer in women at increased risk
- (D) Recommend against routine use if no increased risk

**Folic acid supplementation<sup>22</sup> (UIP)**

- (A) 0.4 to 0.8 mg daily for women capable of conception

**Aspirin for cardiovascular risk reduction<sup>23</sup> (UIP)**

- (A) Recommend aspirin use in men 45 to 79 years of age for reduction in myocardial infarction if benefit outweighs risk
- (A) Recommend aspirin use in women 55 to 79 years of age for reduction in ischemic stroke if benefit outweighs risk
- (I) IETFOA aspirin for primary prevention of cardiovascular risk reduction in individuals 80 years and older
- (D) Recommend against use of aspirin for CVD primary prevention in men younger than 45 years and women younger than 55 years

**Fall prevention in older adults<sup>24</sup> (UIP)**

- (B) Recommend exercise or physical therapy and vitamin D supplementation for fall prevention in community-dwelling individuals 65 years and older at increased risk of falls
- (C) Recommend against automatic comprehensive screening for fall risk in community-dwelling older adults

**Counseling to prevent sexually transmitted infection<sup>25</sup>**

- (B) Recommend counseling to prevent sexually transmitted infection for adolescents and adults at increased risk

**Counseling to promote healthy diet and physical activity<sup>26</sup>**

- (B) Recommend that overweight or obese patients with other CVD risk factor(s) be offered or referred for intensive behavioral counseling

**Counseling for skin cancer prevention<sup>27</sup>**

- (B) Recommend counseling fair-skinned patients 10 to 24 years of age about minimizing ultraviolet light exposure
- (I) IETFOA counseling individuals older than 24 years about reducing risk of skin cancer

**Grade C Recommendations:**

Physical activity and healthy diet counseling to reduce cardiovascular risk<sup>28</sup> (UIP)

**Grade D Recommendations:**

- Aspirin or nonsteroidal anti-inflammatory drugs for prevention of colorectal cancer<sup>29</sup> (UIP)
- Bacteriuria (asymptomatic) screening in men and nonpregnant women<sup>30</sup>
- Beta carotene or vitamin E supplementation for CVD or cancer risk reduction<sup>31</sup>
- Carotid artery stenosis screening<sup>32</sup>
- CHD screening with resting or exercise electrocardiography in low-risk patients<sup>33</sup>
- Chronic obstructive pulmonary disease screening with spirometry<sup>34</sup>
- Combined estrogen-progesterone for prevention of chronic conditions or estrogen for the same in patients with hysterectomy<sup>35</sup> (UIP)
- Genital herpes screening<sup>36</sup> (UIP)
- Ovarian cancer screening<sup>37</sup> (UIP)
- Pancreatic cancer screening<sup>38</sup>
- Prostate cancer screening with prostate-specific antigen<sup>39</sup> (UIP)
- Testicular cancer screening<sup>40</sup>
- Vitamin D screening in community-dwelling nonpregnant adults<sup>41</sup>
- Vitamin D ( $\leq 400$  IU) and calcium ( $\leq 1,000$  mg) supplementation daily for primary prevention of fracture in noninstitutionalized postmenopausal women<sup>42</sup>

**Grade I Recommendations:**

- Bladder cancer screening<sup>43</sup>
- CHD screening with nontraditional risk factors<sup>44</sup> (UIP)
- CHD screening with resting or exercise electrocardiography in intermediate- to high-risk patients<sup>33</sup>
- Chronic kidney disease screening<sup>45</sup>
- Cognitive impairment screening in older adults<sup>46</sup>
- Combined vitamin D and calcium supplementation in men or premenopausal women<sup>42</sup>
- Hearing loss screening in older adults<sup>47</sup>
- Illicit drug use screening<sup>48</sup>
- Impaired visual acuity screening in older adults<sup>49</sup>
- Multivitamin, single nutrient or paired nutrients for CVD or cancer risk reduction (beta carotene and vitamin E, as above)<sup>31</sup>
- Oral cancer screening<sup>50</sup>
- Peripheral artery disease and CVD risk screening with ankle-brachial index<sup>51</sup>
- Primary open-angle glaucoma screening<sup>52</sup>
- Skin cancer screening (whole body) in primary care<sup>53</sup> (UIP)
- Suicide risk screening<sup>54</sup>
- Thyroid dysfunction screening<sup>55</sup>
- Vitamin D ( $> 400$  IU) and calcium ( $> 1,000$  mg) supplementation daily for primary prevention of fracture in noninstitutionalized postmenopausal women<sup>42</sup>

CHD = coronary heart disease; CVD = cardiovascular disease; IETFOA = insufficient evidence to recommend for or against; UIP = update in progress; USPSTF = U.S. Preventive Services Task Force.



## Adult Preventive Health Care Schedule: Recommendations from the USPSTF (continued)

### REFERENCES

- Moyer VA. Screening and behavior counseling interventions in primary care to reduce alcohol misuse: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;159(3):210-218.
- Siu AL. Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement. *JAMA.* 2016;315(4):380-387.
- Siu AL. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2015;163(10):778-786.
- Moyer VA. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(5):373-378.
- Siu AL. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2015;163(8):622-634.
- Moyer VA. Screening for HIV: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;159(1):51-60.
- LeFevre ML. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;161(1):58-66.
- Calonge N. Screening for syphilis infection: recommendation statement [published correction appears in *Ann Fam Med.* 2004;2(5):517]. *Ann Fam Med.* 2004;2(4):362-365.
- Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;160(4):271-281.
- LeFevre ML. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;161(12):902-910.
- Moyer VA. Screening for intimate partner violence and abuse of elderly and vulnerable adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;158(6):478-486.
- Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in *Ann Intern Med.* 2013;158(11):852]. *Ann Intern Med.* 2012;156(12):880-891.
- Screening for lipid disorders in adults [summary]. U.S. Preventive Services Task Force recommendation statement. 2008. <http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening>. Accessed July 1, 2015.
- Sui AL. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2015;163(11):861-868.
- Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;159(5):349-357.
- Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2008;149(9):627-637.
- Siu AL. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2016;164(4):279-296.
- Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;160(5):330-338.
- Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2011;154(5):356-364.
- LeFevre ML. Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;161(4):281-290.
- Moyer VA. Medication for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;159(10):698-708.
- Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009;150(9):626-631.
- Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009;150(6):396-404.
- Moyer VA. Prevention of falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(3):197-204.
- LeFevre ML. Behavioral counseling interventions to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;161(12):894-901.
- LeFevre ML. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;161(8):587-593.
- Behavioral counseling to prevent skin cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(1):59-65.
- Moyer VA. Behavioral counseling interventions to promote a healthful diet and physical activity for cardiovascular disease prevention in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(5):367-372.
- Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2007;146(5):361-364.
- Screening for asymptomatic bacteriuria in adults: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med.* 2008;149(1):43-47.
- Moyer VA. Vitamins, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;160(8):558-564.
- LeFevre ML. Screening for asymptomatic carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement [published correction appears in *Ann Intern Med.* 2015;162(4):323]. *Ann Intern Med.* 2014;161(5):256-262.
- Moyer VA. Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(7):512-518.
- Siu AL. Screening for chronic obstructive pulmonary disease: U.S. Preventive Services Task Force recommendation statement. *JAMA.* 2016;315(13):1372-1377.
- Moyer VA. Menopausal hormone therapy for primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;158(1):47-54.
- Screening for genital herpes [summary]. U.S. Preventive Services Task Force recommendation statement. 2005. <http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/genital-herpes-screening>. Accessed July 1, 2015.
- Moyer VA. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med.* 2012;157(21):900-904.

### Adult Preventive Health Care Schedule: Recommendations from the USPSTF (continued)

38. Screening for pancreatic cancer [summary]. U.S. Preventive Services Task Force recommendation statement. 2004. <http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/pancreatic-cancer-screening>. Accessed July 1, 2015.
39. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(2):120-134.
40. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med.* 2011;154(7):483-486.
41. LeFevre ML. Screening for vitamin D deficiency in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2015;162(2):133-140.
42. Moyer VA. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;158(9):691-696.
43. Moyer VA. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in *Ann Intern Med.* 2011;155(6):408]. *Ann Intern Med.* 2011;155(4):246-251.
44. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009;151(17):474-482.
45. Moyer VA. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(8):567-570.
46. Moyer VA. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;160(11):791-797.
47. Moyer VA. Screening for hearing loss in older adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(9):655-661.
48. Screening for illicit drug use [summary]. U.S. Preventive Services Task Force. 2008. <http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/drug-use-illicit-screening>. Accessed July 1, 2015.
49. Siu AL. Screening for impaired visual acuity in older adults: U.S. Preventive Services Task Force recommendation statement. *JAMA.* 2016;315(9):908-914.
50. Moyer VA. Screening for oral cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;160(1):55-60.
51. Moyer VA. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;159(5):342-348.
52. Moyer VA. Screening for glaucoma: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;159(7):484-489.
53. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009;150(3):188-193.
54. LeFevre ML. Screening for suicide risk in adolescents, adults, and older adults in primary care: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;160(10):719-726.
55. LeFevre ML. Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2015;162(9):641-650.